Patents by Inventor Harry R. Davis

Harry R. Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
    Patent number: 11077092
    Abstract: Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: August 3, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hong-Ping Guan, Jose M. Castro-Perez, Harry R. Davis, Samuel E. Engel, Douglas G. Johns, Songnian Lin, Stephen F. Previs, Thomas P. Roddy, Liangsu Wang, Sheng-Ping Wang, Yusheng Xiong
  • METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR
    Publication number: 20170216250
    Abstract: Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Applicant: Merch Sharp & Dohme Corp.
    Inventors: Hong-Ping Guan, Jose M. Castro-Perez, Harry R. Davis, Samuel E. Engel, Douglas G. Johns, Songnian Lin, Stephen F. Previs, Thomas P. Roddy, Liangsu Wang, Sheng-Ping Wang, Yusheng Xiong
  • METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR
    Publication number: 20150320724
    Abstract: Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
    Type: Application
    Filed: December 8, 2013
    Publication date: November 12, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Hong-Ping Guan, Jose M. Castro-Perez, Harry R. Davis, Samuel E. Engel, Douglas G. Johns, Songnian Lin, Stephen F. Previs, Thomas P. Roddy, Liangsu Wang, Sheng-Ping Wang, Yusheng Xiong
  • Use of azetidinone compounds
    Patent number: 7723020
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: May 25, 2010
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS
    Publication number: 20080261942
    Abstract: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted ?-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
    Type: Application
    Filed: June 11, 2008
    Publication date: October 23, 2008
    Applicant: SCHERING CORPORATION
    Inventors: Harry R. Davis, Teddy Kososglou
  • Use of substituted azetidinone compounds for the treatment of sitosterolemia
    Patent number: 7417039
    Abstract: The present invention is directed to the use of sterol absorption inhibiting compounds, pharmaceutical compositions thereof, therapeutic combinations and their use in combination with other lipid lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: August 26, 2008
    Assignee: Schering Corporation
    Inventor: Harry R. Davis
  • Use of azetidinone compounds
    Patent number: 7144696
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: December 5, 2006
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
    Patent number: 7132415
    Abstract: The present invention provides therapeutic combinations and methods including at least one sterol or 5?-stanol absorption inhibitor that can be useful for treating xanthomas.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: November 7, 2006
    Assignee: Schering Corporation
    Inventor: Harry R. Davis
  • Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
    Patent number: 7071181
    Abstract: The present invention provides methods of treating diabetes and associated conditions by administering a composition including at least one sterol or 5?-stanol absorption inhibitor or compositions or therapeutic combinations including: (a) at least one antidiabetic medication; and (b) at least one sterol or 5?-stanol absorption inhibitor.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: July 4, 2006
    Assignee: Schering Corporation
    Inventors: Harry R. Davis, Teddy Kosoglou, Gilles J. Picard, Rudyard J. Ress, John T. Strony, Enrico P. Veltri
  • Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
    Patent number: 7053080
    Abstract: The present invention provides methods for the treatment of obesity using sterol or 5?-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5?-stanol absorption inhibitors and at least one obesity control medication.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: May 30, 2006
    Assignee: Schering Corporation
    Inventors: Harry R. Davis, Rudyard J. Ress, John T. Strony, Enrico P. Veltri
  • Substituted 2-azetidinones useful as hypocholesterolemic agents
    Patent number: 6982251
    Abstract: Hypocholesterolemic substituted 2-azetidinone compounds of the formula: are disclosed, as well as a methods of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: January 3, 2006
    Assignee: Schering Corporation
    Inventors: Anima Ghosal, Shmuel Zbaida, Swapan K. Chowdhury, Robert M. Iannucci, Wenqing Feng, Kevin B. Alton, James E. Patrick, Harry R. Davis
  • Use of azetidinone compounds
    Patent number: 6933107
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: August 23, 2005
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
    Publication number: 20040214811
    Abstract: The present invention provides methods of treating diabetes and associated conditions by administering a composition including at least one sterol or 5&agr;-stanol absorption inhibitor or compositions or therapeutic combinations including: (a) at least one antidiabetic medication; and (b) at least one sterol or 5&agr;-stanol absorption inhibitor.
    Type: Application
    Filed: September 19, 2002
    Publication date: October 28, 2004
    Applicant: Schering Corporation
    Inventors: Harry R. Davis, Teddy Kosoglou, Gilles J. Picard, Rudyard J. Ress, John T. Strony, Enrico P. Veltri
  • Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
    Publication number: 20040097482
    Abstract: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one HM74 or HM74A agonist and (b) at least one substituted azetidinone or substituted &bgr;-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
    Type: Application
    Filed: August 13, 2003
    Publication date: May 20, 2004
    Applicant: Schering Corporation
    Inventors: Harry R. Davis, Teddy Kosoglou, Michael P. Graziano, Joseph A. Hedrick
  • Use of azetidinone compounds
    Publication number: 20030215869
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Application
    Filed: May 15, 2003
    Publication date: November 20, 2003
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Use of azetidinone compounds
    Patent number: 6632933
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: October 14, 2003
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Use of azetidinone compounds
    Patent number: 6593078
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: July 15, 2003
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
    Publication number: 20030119809
    Abstract: The present invention provides therapeutic combinations and methods including at least one sterol or 5&agr;-stanol absorption inhibitor that can be useful for treating xanthomas.
    Type: Application
    Filed: September 19, 2002
    Publication date: June 26, 2003
    Applicant: Schering Corporation
    Inventor: Harry R. Davis
  • Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
    Publication number: 20030119428
    Abstract: The present invention provides methods for the treatment of obesity using sterol or 5&agr;-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5&agr;-stanol absorption inhibitors and at least one obesity control medication.
    Type: Application
    Filed: September 19, 2002
    Publication date: June 26, 2003
    Applicant: Schering Corporation
    Inventors: Harry R. Davis, Rudyard J. Ress, John T. Strony, Enrico P. Veltri
  • Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
    Publication number: 20030119808
    Abstract: The present invention relates to methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects associated with certain HMG-CoA reductase inhibitors by coadministration of at least one sterol or 5&agr;-stanol absorption inhibitor, pharmaceutically acceptable salts or solvates thereof, and at least one HMG-CoA reductase inhibitor, the latter being used sparingly in amounts insufficient to cause muscle degeneration.
    Type: Application
    Filed: September 19, 2002
    Publication date: June 26, 2003
    Applicant: Schering Corporation
    Inventors: Alexandre P. LeBeaut, Harry R. Davis